Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Indivior Pharmaceuticals (INDV) Accounts Payables (2021 - 2025)

Indivior Pharmaceuticals (INDV) has 4 years of Accounts Payables data on record, last reported at $196.0 million in Q2 2025.

  • For Q2 2025, Accounts Payables changed N/A year-over-year to $196.0 million; the TTM value through Jun 2025 reached $196.0 million, changed N/A, while the annual FY2024 figure was $216.0 million, 10.77% up from the prior year.
  • Accounts Payables reached $196.0 million in Q2 2025 per INDV's latest filing, down from $216.0 million in the prior quarter.
  • Across five years, Accounts Payables topped out at $617.0 million in Q4 2022 and bottomed at $195.0 million in Q4 2023.
  • Average Accounts Payables over 4 years is $306.0 million, with a median of $206.0 million recorded in 2024.
  • Peak YoY movement for Accounts Payables: crashed 68.4% in 2023, then increased 10.77% in 2024.
  • A 4-year view of Accounts Payables shows it stood at $617.0 million in 2022, then plummeted by 68.4% to $195.0 million in 2023, then rose by 10.77% to $216.0 million in 2024, then dropped by 9.26% to $196.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Accounts Payables were $196.0 million in Q2 2025, $216.0 million in Q4 2024, and $195.0 million in Q4 2023.